Is ImClone Out of the Woods?
Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth
Comments are closed.
Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth
Comments are closed.